Voyager Therapeutics, Inc.

NASDAQ:VYGR

Biotechnology

Healthcare
$1.67 +2.35%

+$0.09 today

Market cap
$103.92M
Beta
1.25
P/E (TTM)
-1.9
EPS (TTM)
-$1.96
52W Low $2.83High $5.55

Volume 0.84M

Average 0.54M

VYGR Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Voyager Therapeutics, Inc.NASDAQ: VYGR

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 42.1% from a year ago

Cash & equivalents stood at $43.31M at the end of Q1 FY2026, down 42.1% from a year earlier and down 33.7% from the prior quarter. Over 3 fiscal years it compounded at -12.9% a year.

Context

  • Cash & equivalents amounted to 19.7% of total assets at the end of Q1 FY2026, down 1.4 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -42.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$43.31M-33.7% QoQ
Last fiscal yearDec 2025
$65.3M-8.5% YoY
Year agoMar 2025
$74.76M-42.1% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.1%——
1 year-8.5%——
3-year CAGR-12.9%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
65.3M USD
Year-over-year change
-8.5%
4-year CAGR
-13.6%

Cash & Equivalents vs competitors

How VYGR compares with its peers on the latest reported figures

  • VYGR's Mar 2026 cash & equivalents of $43.31M is the 6th highest of the 11 companies compared; the peer median is $42.58M.
  • Its year-over-year change of -42.1% is the 8th highest of 11, against a peer median of -31.1%.
  • Cash & equivalents amounts to 19.7% of total assets for VYGR, versus a peer median of 26.2%.
VYGR Competitors Peer median
Cash & Equivalents for VYGR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$211.38M -2.6%-16.2%86.1%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$79.32M -33.6%-47.1%29.7%
TRDAEntrada Therapeutics, Inc.Mar 2026$76.44M +12.7%+26.0%22.8%
VNDAVanda Pharmaceuticals Inc.Mar 2026$54.03M -51.7%-14.3%12.5%
HUMAHumacyte, Inc.Mar 2026$48.54M -22.8%-30.4%43.9%
VYGRVoyager Therapeutics, Inc.Mar 2026$43.31M -42.1%-12.9%19.7%
SGMTSagimet Biosciences Inc.Mar 2026$36.63M -43.4%+505.2%34.0%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$34.93M -42.0%-9.8%11.1%
ALLOAllogene Therapeutics, Inc.Mar 2026$30.31M -28.6%-5.8%7.7%
ACHVAchieve Life Sciences, Inc.Mar 2026$28.08M +115.7%-5.4%84.8%
PYXSPyxis Oncology, Inc.Mar 2026$7.24M -43.3%-55.9%11.3%
Peer median (excluding VYGR) $42.58M-31.1%-12.1%26.2%

Competitors are the stored peer set for VYGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents117.43M98.96M68.8M71.37M65.3M
Short-term Investments15.11M19.89M162.07M195.32M131.15M
Net Receivables748K639K84.46M4.49M1.76M
Inventory00000
Other Current Assets1.7M4.23M2.63M2.87M4.48M
Total Current Assets136.7M124.5M319.68M276.81M202.69M
Property, Plant & Equipment (Net)55.38M33.34M30M47.66M41.61M
Goodwill00000
Intangible Assets00000
Long-term Investments00065.7M0
Tax Assets00000
Other Non-current Assets1.78M1.52M1.59M2.87M7.98M
Total Non-current Assets57.16M34.86M31.6M116.24M49.59M
Total Assets193.86M159.36M351.28M393.05M252.28M
Account Payables574K2.57M1.6M4M5.01M
Short-term Debt00000
Tax Payables00000
Deferred Revenue33.89M59.38M42.88M24.39M1.59M
Other Current Liabilities5.02M4.56M6.61M6.75M9.09M
Total Current Liabilities50.98M72.59M64.51M49.79M26.54M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)8.21M6.45M32.36M6M0
Other Non-current Liabilities1M1M1M1M1M
Total Non-current Liabilities47.82M27.75M50.45M43.5M29.66M
Total Liabilities98.8M100.34M114.96M93.29M56.2M
Common Stock38K38K44K55K59K
Retained Earnings(347.1M)(393.51M)(261.18M)(326.18M)(445.91M)
Accumulated OCI(138K)(219K)(48K)(407K)32K
Other Stockholders Equity00000
Minority Interest00000
Total Equity95.06M59.02M236.32M299.76M196.08M
Total Debt44.18M23.13M20.29M43.73M36.5M
Net Debt(73.25M)(75.83M)(48.51M)(27.64M)(28.8M)

Voyager Therapeutics, Inc.

NASDAQ:VYGR

Intrinsic Alpha fair value

Locked

Current Price

$1.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.